Biotech News

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics (VIRX)Viracta Therapeutics2024-09-05 15:32 ESTConference / presentation

VIRX (VIRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is virx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

View all latest news

Viracta Therapeutics

Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology. Its platform aims to treat tumors linked to latent viral drivers.

Recent company news

VIRXViracta Therapeutics2025-02-05 22:00 EST

Viracta Therapeutics Announces Wind Down of Operations

VIRXViracta Therapeutics2024-12-26 21:30 EST

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

VIRXViracta Therapeutics2024-11-13 12:00 EST

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VIRXViracta Therapeutics2024-11-06 20:19 EST

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

VIRXViracta Therapeutics2024-09-05 15:32 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States